Today, Wednesday, May 27, marks the final opportunity for investors to acquire shares of Bajaj Auto Ltd and GlaxoSmithKline Pharmaceuticals Ltd (GSK Pharma) and qualify for their substantial upcoming dividends. Due to a market holiday on Thursday, May 28, for Bakri Id, the usual settlement cycle is truncated, making today the effective last day to buy.
Dividend Eligibility: Record Date and Last Buy Date
Both Bajaj Auto and GSK Pharma have set Friday, May 29, 2026, as the record date. This date is crucial for determining which shareholders are eligible to receive dividends for the financial year concluded on March 31, 2026. Typically, investors would have until Thursday to secure their positions, but the upcoming Bakri Id holiday on May 28 means the market will be closed. Consequently, any shares purchased after today will not settle in time to be registered by the record date.
Bajaj Auto's Generous Payout
As per its exchange filing, Bajaj Auto has proposed a significant dividend of Rs 150 per equity share, based on a face value of Rs 10. This recommendation awaits approval at the company's Annual General Meeting (AGM) slated for July 21, 2026. If approved, the dividend payments are expected to be distributed to eligible shareholders on or around July 24, 2026.
GSK Pharma's Final Dividend
GlaxoSmithKline Pharmaceuticals Ltd has recommended a final dividend of Rs 57 per equity share, also resting on a face value of Rs 10. Subject to shareholder approval, the company has indicated that the dividend payments would be disbursed on and after Wednesday, July 1. Investors looking to benefit from this payout must ensure their stock purchases are completed before the market closes today.
The shortened trading week underscores the urgency for investors. Those seeking a share of these dividend payouts must finalize their stock acquisitions today, May 27, ahead of the closing bell.
This alert serves as an important reminder for investors to act promptly if they wish to be eligible for the announced dividends from Bajaj Auto and GSK Pharma.